Imetelstat: Phase II started

Johnson & Johnson’s Janssen Biotech Inc. unit began the single-blind, international Phase II IMbark trial to evaluate 4.7 and 9.4 mg/kg IV imetelstat every 3 weeks in about 200 patients with intermedi...